Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Oncolytics Biotech ( (ONCY) ) is now available.
Oncolytics Biotech Inc. has rescheduled its special meeting of shareholders to January 15, 2026, to vote on changing its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA. This move aims to reduce regulatory burdens and costs, aligning with the company’s strategic goals to enhance shareholder value and operational efficiency, given its significant operations and shareholder base in the United States.
The most recent analyst rating on (ONCY) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. The company targets various cancers, including pancreatic and breast cancers, and is working on strategic partnerships to enhance development and commercial impact.
Average Trading Volume: 922,781
Technical Sentiment Signal: Sell
Current Market Cap: $105.3M
Find detailed analytics on ONCY stock on TipRanks’ Stock Analysis page.